For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival (“PFS”) was 12.4 months with gedatolisib + palbociclib + fulvestrant (“gedatolisib ...
Serum levels of suppressor of cytokine signalling 2 are significantly elevated in children with CKD and are independently ...
November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies ...
A recent breast cancer vaccine brings good news for women. The jab could help prevent Triple-negative breast cancer (TNBC) ...
This study conducts a performance evaluation of a blockchain-based Human Resource Management System (HRMS) utilizing smart ...
Intensity Therapeutics, Inc. ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent ...
Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell ...
Baystreet.ca News Commentary – The 2025 American Society of Hematology meeting showcased pivotal advances in blood cancer ...
From balls and launch monitors to pants, clubs and shoes, we found the best holiday golf gifts at the best prices for 2025.
PRESS RELEASEAB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS ...
The Porsche 911 is a delicious confection of driving pleasure. Also true: Every 911 that emerges from the Porsche patisserie ...
S&P 500 may hit 7,800 by 2026, fueled by tech and AI growth. Discover top defense AI stocks to watch amid rising US, NATO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback